Anti-D Immunoglobulin Market Report 2026

The anti-d immunoglobulin market size has grown strongly in recent years. It will grow from $2.59 billion in 2025 to $2.76 billion in 2026 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to limited plasma donor pools, reliance on manual antibody extraction processes, growing awareness of hemolytic disease, increasing hospital and clinical usage, adoption of intramuscular administration.

The anti-d immunoglobulin market size is expected to see strong growth in the next few years. It will grow to $3.55 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to development of intravenous formulations, expansion of automated plasma fractionation technologies, rising antenatal screening programs, increasing global blood bank infrastructure, growth in personalized immunoglobulin therapies. Major trends in the forecast period include rising demand for anti-d immunoglobulin in hemolytic disease management, increasing adoption of pre-filled syringes and single-use vials, expansion of antenatal and postnatal prophylaxis programs, growth in hospital and blood bank-based distribution channels, enhanced focus on safety, purity, and regulatory compliance.

The high birth rates are anticipated to drive the growth of the anti-D immunoglobulin market in the coming years. Birth rates refer to the number of live births recorded each year per 1,000 individuals in a population. Birth rates are rising due to limited access to education and family planning services, which leads to higher fertility levels and larger family sizes. Anti-D immunoglobulin supports positive pregnancy outcomes by preventing Rh incompatibility, thereby reducing the risk of hemolytic disease in newborns and promoting healthier outcomes in subsequent pregnancies. For instance, in April 2025, according to the Centers for Disease Control and Prevention, a US-based government agency, there were 3,622,673 births recorded in 2024, representing a 1% increase compared to 2023. Therefore, the high birth rates are contributing to the growth of the anti-D immunoglobulin market.

The expansion of healthcare infrastructure is expected to further propel the growth of the anti-D immunoglobulin market going forward. Healthcare infrastructure encompasses the network of facilities, medical equipment, healthcare professionals, and support systems required to deliver healthcare services to a population. The expansion of healthcare infrastructure is driven by global population growth, which increases demand for medical services and necessitates the development of additional hospitals, clinics, and healthcare resources. Improved healthcare infrastructure enhances access to maternal healthcare services, allowing for better screening and timely administration of anti-D immunoglobulin to prevent hemolytic disease in newborns. For instance, in May 2023, according to the Department of Health and Social Care, a UK-based government department, the government announced plans to invest more than $27 billion (£20 billion) in the construction of new hospital facilities. Under the New Hospital Programme, two hospitals had already been completed, five were under construction, and more than 20 were scheduled to begin or be completed by the end of 2023. Therefore, the expansion of healthcare infrastructure is supporting the growth of the anti-D immunoglobulin market.

The growth of prenatal and antenatal screening programs is expected to drive the expansion of the anti-D immunoglobulin market in the coming years. Prenatal and antenatal screening involves testing pregnant women for blood group compatibility and determining fetal RhD genotype to prevent hemolytic disease of the fetus and newborn. The expansion of these screening programs is largely attributed to the adoption of noninvasive prenatal testing (NIPT) using cell-free fetal DNA, which enables accurate detection of fetal RhD status. Prenatal and antenatal screening programs facilitate the effective use of anti-D immunoglobulin by enabling early identification of Rh-negative mothers, monitoring potential sensitization events, and ensuring timely intervention to prevent Rh incompatibility while safeguarding maternal and fetal health. For instance, in July 2025, according to the World Health Organization (WHO), a Switzerland-based global public health agency, approximately 1.2 million pregnant women were living with HIV in 2023, with about 84% receiving antiretroviral treatment to prevent mother-to-child transmission. Therefore, the expansion of prenatal and antenatal screening programs is driving the growth of the anti-D immunoglobulin market.

Major companies operating in the anti-d immunoglobulin market are CSL Behring, Octapharma AG, Kedrion Biopharma Inc., Biotest AG, Sanquin, Bharat Serums and Vaccines Limited, Intas Pharmaceuticals Ltd., Zydus Lifesciences Limited, Emergent BioSolutions Inc., Kamada Pharmaceuticals, Saol Therapeutics Inc., Avin Darou, Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Taj Pharmaceuticals Limited, Aetos Pharma Private Limited, PV Pharma Healthcare Pvt. Ltd., Grifols S.A., Takeda Pharmaceutical Company Limited, LFB Biomedicaments, China Biologic Products Holdings Inc., Shanghai RAAS Blood Products Co. Ltd., Hualan Biological Engineering Inc., CBPO (Shandong Taibang Biological Products Co. Ltd.), Bio Products Laboratory (BPL), Instituto Grifols S.A., HemaCare Corporation, KM Biologics Co. Ltd., National Bioproducts Institute (NBI), GC Pharma (Green Cross Corporation), SK Plasma Co. Ltd.

North America was the largest region in the anti-D immunoglobulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-d immunoglobulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anti-d immunoglobulin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the anti-D immunoglobulin market by increasing costs of imported raw plasma and specialized production equipment. Segments such as intravenous formulations and pre-filled syringes are particularly impacted, with Asia-Pacific regions including India and China facing higher import duties. These tariffs have resulted in increased production costs and supply chain adjustments. Positively, tariffs are driving local production initiatives, encouraging investment in domestic plasma fractionation facilities, and fostering innovation in formulation technologies.

The anti-d immunoglobulin market research report is one of a series of new reports that provides anti-d immunoglobulin market statistics, including anti-d immunoglobulin industry global market size, regional shares, competitors with a anti-d immunoglobulin market share, detailed anti-d immunoglobulin market segments, market trends and opportunities, and any further data you may need to thrive in the anti-d immunoglobulin industry. This anti-d immunoglobulin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anti-D immunoglobulin is a specialized blood-derived product obtained from human plasma that contains antibodies directed against the RhD antigen present on red blood cells. It is manufactured by collecting plasma from donors sensitized to the RhD antigen, followed by the purification and concentration of specific immunoglobulin G (IgG) antibodies.

The main product types of anti-D immunoglobulin include intramuscular anti-D immunoglobulin and intravenous anti-D immunoglobulin. Intramuscular anti-D immunoglobulin is a plasma-derived antibody formulation administered into muscle tissue to prevent Rh incompatibility in Rh-negative individuals by neutralizing Rh-positive fetal red blood cells. These products are distributed through multiple channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others, and are used in applications such as hemolytic disease of the newborn, immune thrombocytopenic purpura, antenatal and postnatal prophylaxis, and other indications. They are utilized by various end users, including hospitals, clinics, blood banks, and research laboratories.

The anti-D immunoglobulin market consists of sales of hepatitis B immunoglobulin, tetanus immunoglobulin, rabies immunoglobulin, and varicella-zoster immunoglobulin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.